menu
    • menu

    Company profile for Odyssey Therapeutics

    NEW Drugs in Dev: 2
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.Odyssey has developed a strategy to create a portfolio of medicines that will go beyond the boundaries of today. By focusing on key signaling nodes that drive disease, we aim to achieve optimal product profiles and min...
    At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.Odyssey has developed a strategy to create a portfolio of medicines that will go beyond the boundaries of today. By focusing on key signaling nodes that drive disease, we aim to achieve optimal product profiles and minimize biologic attrition while maximizing the clinical benefit of each therapeutic.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Odyssey TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    301 Binney Street, Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://odysseytx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/odyssey-tx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Odyssey Nears $900M Valuation as Shares Surge on Nasdaq Debut
    Odyssey Nears $900M Valuation as Shares Surge on Nasdaq Debut

    08 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biotech-firm-odyssey-valued-8999-million-shares-rises-nasdaq-debut-2026-05-08/

    REUTERS
    08 May 2026
    Share Share
    Biotech firm Odyssey targets $810 million valuation in US IPO
    Biotech firm Odyssey targets $810 million valuation in US IPO

    04 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biotech-firm-odyssey-targets-810-million-valuation-us-ipo-2026-05-04/

    REUTERS
    04 May 2026
    Share Share
    Odyssey Therapeutics Eyes IPO in Improving Market
    Odyssey Therapeutics Eyes IPO in Improving Market

    20 Apr 2026

    // ENDPOINTS

    https://endpoints.news/odyssey-therapeutics-will-try-again-to-ipo-this-time-in-a-warmer-market/

    ENDPOINTS
    20 Apr 2026
    Share Share
    Odyssey Therapeutics Refiles for $100M IPO in Autoimmune Diseases
    Odyssey Therapeutics Refiles for $100M IPO in Autoimmune Diseases

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7188007

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Odyssey Appoints H. Martin to Scientific Advisory Board
    Odyssey Appoints H. Martin to Scientific Advisory Board

    10 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-10/odyssey-therapeutics-appoints-h-martin-seidel-phd-to-scientific-advisory-board

    PHARMIWEB
    10 Mar 2026
    Share Share
    Odyssey Therapeutics Taps Jolie Siegel as EVP, General Counsel
    Odyssey Therapeutics Taps Jolie Siegel as EVP, General Counsel

    21 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260121775858/en/Odyssey-Therapeutics-Appoints-Jolie-M.-Siegel-as-Executive-Vice-President-General-Counsel

    BUSINESSWIRE
    21 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search